AU2021107007A4

AU2021107007A4 - Use of walnut extract in preparing medicine for treating burn wounds

Info

Publication number: AU2021107007A4
Application number: AU2021107007A
Authority: AU
Inventors: Yinsheng Wu; Yan Xie
Original assignee: General Hospital of Ningxia Medical University
Current assignee: General Hospital of Ningxia Medical University
Priority date: 2021-04-16
Filing date: 2021-08-24
Publication date: 2021-12-02
Anticipated expiration: 2029-08-24
Also published as: CN112915117A

Abstract

The invention provides the use of walnut extract in the preparation of a medicine for treating burn wounds. The inventor found that the walnut extract of the present application can treat burn wounds. It has significant therapeutic effects, including anti-infection, inhibiting scar hyperplasia, non-toxic side effects, convenient use, easy absorption, economical benefits, effectively promoting the repair of hard-to-heal burn wounds. It provides patients with an efficient, economical, convenient and practical treatment for hard-to-heal burn wounds. It greatly reduces the burden on patients, and effectively compensates for the existing defects in the treatment of hard-to-heal burn wounds. 1/1 DRAWINGS bc def Figure 1 Creation of porcine non-healing burn wound models. (a) A burn wound formation. (b) Histological analysis of the burn wound (x 40 magnification) 24 hours after burn injury. (c) High magnification view of the area indicated in lb (x 100 magnification).(d) The eschar formation at 3 weeks after burn injury; (e) Clearance of necrotic eschar at 3 weeks after burn injury and creation of porcine non-healing burn wounds; (f) The wounded porcine.

Description

1/1

DRAWINGS

bc

def

Figure 1

Creation of porcine non-healing burn wound models. (a) A burn wound formation. (b) Histological analysis of the burn wound (x 40 magnification) 24 hours after burn injury. (c) High magnification view of the area indicated in lb (x 100 magnification).(d) The eschar formation at 3 weeks after burn injury; (e) Clearance of necrotic eschar at 3 weeks after burn injury and creation of porcine non-healing burn wounds; (f) The wounded porcine.

USE OF WALNUT EXTRACT IN PREPARING MEDICINE FOR TREATING BURN WOUNDS

[0001] This application claims the benefit of priority to the Chinese patent application No.

CN202110414289.1, filed before China National Intellectual Property Administration on April 16,

2021, entitled "Use of walnut extract in preparing medicine for treating burn wounds", all of

which are incorporated herein by reference.

TECHNICAL FIELD

[0002] The invention relates to the technical field of new uses of walnut extracts, in particular

to the use of walnut extracts in preparing medicines for treating burn wounds.

BACKGROUND

[0003] Burns are damages to the skin or other tissues or organs that are mainly caused by high

temperature, or caused by radiation, electricity, friction, or exposure to chemicals. Burns bring

a huge economic burden to the country and society. Non-fatal burn wounds, such as

hard-to-heal wounds, cause huge mental trauma, physical pain and heavy economic burdens to

patients.

[0004] The non-healing burn wound frequently occurs over a long period of time after a burn

injury, carrying a risk of relapse and carcinogenesis. It remains a difficult problem to develop a

treatment for the non-healing burn wound suitable for clinic use, which is also important for

the research in the field of burns. A novel therapy for treating non-healing burn wounds is

urgently required.

SUMMARY

[0005] In the long-term study, the inventor found that walnut extract has excellent therapeutic

effect on the burn wound surface, especially the burn hard-to-heal surface, and based on the

discovery, the present invention is completed.

[0006] The first aspect of the application provides the use of walnut extract in the preparation

of a medicine for treating burn wounds, wherein the walnut extract contains the following

ingredients: Linolenic acid 250-300mg/g, Stearic acid 8-12 mg/g, Oleyl palmitamide 13-17 mg/g,

Octadecanamide 8-12 mg/g, Tannic acid 10-15 mg/g, tyrosol 28-32mg/g, Oleamide 68-72mg/g

and Activated charcoal 100-150 mg/g.

[0007] The second aspect of the application provides a pharmaceutical composition comprising

a walnut extract and a pharmaceutically acceptable carrier and/or excipient, wherein the

walnut extract contains the following ingredients: Linolenic acid 250-300mg/g, Stearic acid 8-12

mg/g, Oleyl palmitamide 13-17 mg/g, Octadecanamide 8-12 mg/g, Tannic acid 10-15 mg/g,

tyrosol 28-32mg/g, Oleamide 68-72mg/g and Activated charcoal 100-150 mg/g.

[0008] The third aspect of the present application provides the use of the pharmaceutical

composition of the second aspect of the present application in preparing a medicine for

treating burn wounds.

[0009] The inventor found that the walnut extract of the present application can treat burn

wounds. It has significant curative effect, anti-infection, inhibiting scar hyperplasia, non-toxic

side effects, convenient use, easy absorption, economical benefits, etc, effectively promoting

the repair of hard-to-heal burn wounds. It provides patients with an efficient, economical,

convenient and practical treatment for hard-to-heal burns, which greatly reduces the burden

on patients, and effectively compensates for the existing defects in the treatment of

hard-to-heal burns.

DESCRIPTION OF THE DRAWINGS

[0010] In order to explain more clearly the Examples of the present invention and the technical

solutions in the art, the drawings used in the Examples and the prior art are briefly described

below. It is obvious for those skilled in the art that the following drawings are only some

embodiments of the present invention, from which other drawings can be obtained without

any creative efforts.

[0011] Figure 1. Creation of porcine non-healing burn wound models. (a) A burn wound

formation. (b) Histological analysis of the burn wound (x 40 magnification) 24 hours after burn

injury. (c) High magnification view of the area indicated in lb (x100 magnification. (d) The

eschar formation at 3 weeks after burn injury. (e) Clearance of necrotic eschar at 3 weeks after

burn injury and creation of porcine non-healing burn wounds. (f) The wounded porcine.

[0012] Figure 2. Effects of this invention on porcine non-healing burn wounds. Gross

appearance of wounds. Wounds were treated with this invention, rhEGF and saline for 1, 2, 3

and 4 weeks.

[0013] Figure 3. Histologic and immunohistochemical analysis of the effects of this invention on

porcine non-healing burn wounds. Immunohistochemical analysis of CK10, P63 in newly formed

epidermis (x 200 magnifications). Scale bar = 100 pm.

DESCRIPTION OF THE INVENTION

[0014] The invention is further described with reference to the following drawings and

embodiments, so that the objectives, the technical solutions, and the advantages of the present

invention are understood more clearly. It is obvious that the embodiments as described are

only some embodiments, rather than all embodiments of the present invention. Based on the

embodiments of the present invention, all other embodiments obtained by those skilled in the

art without creative effort shall fall within the protection scope of the present invention.

[0015] The first aspect of the application provides the use of walnut extract in the preparation

and Activated charcoal 100-150 mg/g. Wherein, the Activated charcoal refers to the content of

carbon element in the walnut extract, which can be understood as elemental carbon produced

by carbonization of some organic matter due to high temperature during the frying process.

[0016] This application does not limit the preparation method of walnut extract, as long as it

can achieve the purpose of the present invention. Illustratively, the walnut extract can be

prepared by the following method: crushing walnuts to 80-120 mesh, stir-frying at 120°C-140°C for 20-40 minutes, grinding, sterilizing at 120°C-125°C for 20-30 minutes to obtain the walnut extract.

[0017] The inventor found that the frying temperature has a greater impact on the content of

the ingredients in the walnut extract, which is not limited to any theory. The inventor found

that if the frying temperature is too high, the effective ingredients in the extract will be

destroyed, thereby reducing the therapeutic effect of the walnut extract. The inventor also

found that the sterilization conditions affect the efficacy of walnut extract. If the temperature is

too low or the time is too short, the sterilization effect cannot be achieved; and if the

sterilization temperature is too high or the sterilization time is too long, the therapeutic effect

of the walnut extraction will be reduced. The inventors found that the obtained walnut extract

has a better therapeutic effect on burn wounds, when crushing walnuts to 80-120 mesh,

stir-frying at 120°C-140°C, and sterilizing at 120°C-125°C.

[0018] In some embodiments of the first aspect of the present application, the burn wound is a

non-healing burn wound.

[0019] In this application, the non-healing burn wound is the same as the clinical definition of

the hard-to-heal burn wound. The non-healing burn wound usually refers to the wound caused

by severe burns that has not healed and has no tendency to heal or has multiple drug-resistant

bacterial infections after 1 month of conventional treatment.

[0020] The walnut extract has an excellent therapeutic effect, especially on hard-to-heal burn

wounds, so it can be used to prepare a medicine for the treatment of burn wounds; in

particular, it can be used to prepare a medicine for hard-to-heal burn wounds.

[0021] As used herein, the term "treatment" has its general meaning, and specifically refers to

the treatment of burn wounds in order to treat, cure, relieve, and relieve the burn wounds.

[0022] The second aspect of the application provides a pharmaceutical composition comprising

walnut extract contains the following ingredients: Linolenic acid 250-300mg/g, Stearic acid 8-12 mg/g, Oleyl palmitamide 13-17 mg/g, Octadecanamide 8-12 mg/g, Tannic acid 10-15 mg/g, tyrosol 28-32mg/g, Oleamide 68-72mg/g and Activated charcoal 100-150 mg/g.

[0023] Conventional techniques in the field of pharmaceutical preparation can be used to

obtain the active ingredients of the raw materials of the pharmaceutical composition of the

present invention, that is, the walnut extract. It is mixed with one or more pharmaceutically

acceptable carriers and then formed into the desired dosage form to prepare the

pharmaceutical composition of the present invention. In some embodiments of the second

aspect of the present application, the dosage form of the pharmaceutical composition is an

ointment, and the ointment can be prepared according to a conventional method in the

pharmaceutical field. In this application, the ointment can be applied to burn wounds for the

treatment of burn wounds.

[0024] As used herein, "pharmaceutically acceptable" means that there is no substantial toxic

effect in the usual dosages, so that it can be approved by the government or an international

organization equivalent to it or has been approved for use in animals, more particularly for

humans, or is registered in the pharmacopoeia.

[0025] The "pharmaceutically acceptable carrier" usable in the pharmaceutical composition of

the present invention may be any conventional carrier in the field of pharmaceutical

preparations, and the choice of a specific carrier will depend on the mode of administration or

the type and state of disease used to treat a specific patient. The preparation of suitable

pharmaceutical compositions for specific dosing patterns is entirely within the knowledge of

the pharmaceutical technicians. For example, the pharmaceutically acceptable carrier and/or

excipient may be selected from at least one of the solvents, thinners, dispersants, suspension

agents, surfactants, isoperage agents, thickeners, emulsifiers, preservatives, adhesives,

lubricants, hydrants, emulsifiers, absorbents, colorants, fragrances, release agents, coating

agents, flavoring agents and antioxidants.

[0026] The third aspect of this application provides the use of the pharmaceutical composition

in the preparation of burn wound treatment in the second aspect of this application.

[0027] In some embodiments of the third aspect of this application, the burn wound is

non-healing burn wounds.

[0028] Example 1 Preparation and composition analysis of walnut extract

Shell 1000 g of walnuts to obtain 500 g of walnut kernels, pulverizing to 100 meshes, frying at

about 130°C for 30 minutes, grinding, and sterilizing in a pulse vacuum sterilizer at 121 degrees

for 20 minutes to obtain 400 g of the walnut extract. Take 100 mg of the walnut extract and

analyze the walnut extract by inductively coupled plasma emission spectrometry, ultraviolet-visible spectrophotometer, Fourier transform micro-infrared spectroscopy, gas

chromatography mass spectrometry, and X-ray energy spectroscopy. Component analysis

showed that the walnut extract contains 28.78 mg Linolenic acid, 0.93 mg Stearic acid, 1.57 mg

Oleyl palmitamide, 0.98 mg Octadecanamide, 1.38 mg Tannic acid, 2.98 mg tyrosol, 7.06 mg

Oleamide 68-72mg/g and 12.38 mg Activated charcoal.

[0029] Example 2 Establishment of animal model of non-healing burn wounds

Animal ethics: The ethics of animal experiments has been approved. The animals used in the

experiment have been treated humanely, and the experiment process complied with the

relevant provisions of the "Animal Health and Protection Law" and the "Code of Practice for

Animal Care and Use for Scientific Research Purposes".

[0030] Experimental animals: experimental grade Guangxi Bama miniature pigs (Tianjin Bainong

Experimental Animal Breeding Technology Co., Ltd.), weighing 19-21Kg, female were raised in a

single cage. After thoroughly disinfecting the animal breeding room and cages with disinfectant

and ultraviolet lamps, the animals are accommodated. Animal feeding is 150g/time, twice a day,

with sufficient water, natural light irradiation, and room temperature controlled at about 25°C.

Disinfect the breeding room and cage regularly every week, and clean the feed trough and

water trough before each feeding.

[0031] Modelling of hard-to-heal wounds of pigs: After regular raising of small pigs, fasting with

water for 12 hours, lying on one side, and injecting Sumian xin into the hip muscles. After the

anesthesia takes effect, transfer to the operating table and place a snorkel in the mouth. After

disinfection of the back of the ear, an indwelling needle of the auricle vein is placed for adequate analgesia and sedation. The surgical area on the back is prepared, disinfected with iodophor; a sterile sheet is spread, and the site of the expected scald is marked. Heat the aluminum block mold (the net weight of the aluminum block mold is 265g, and the load is 1kg) to 96°C for 10 minutes. The mold was in close contact with the skin for 45 seconds. After the operation, disinfect with iodophor, apply cotton pad dressing and elastic sleeve to fix it.

Antibiotics were injected intravenously to prevent infection, and 2ml of the awakening agent Lu

Xingning was injected intravenously, and then transferred to a cage. One hour after waking up,

give oral rehydration salt and drink water. Closely observe activities and signs. Figure 1 shows

the modelling process of pig non-healing burn wounds.

[0032] Example 3 Animal burn wound healing experiment

Evaluation of curative effect of repairing hard-to-heal wounds

In order to verify the therapeutic effect of the present invention on burn wounds, the walnut

extract, the recombinant human epidermal growth factor (rhEGF) (20001U/mL, 15mL, Shenzhen

Huashengyuan Genetic Engineering Development Co., Ltd., and physiological saline (NS) were

used to treat pigs with hard-to-heal burn wounds. Figure 2 shows the healing of residual

wounds on the 7, 14, 21, and 28 days.

[0033] Residual wound area (%) = (area after treatment/area before treatment) x 100%; wound

healing rate (%) = (area before treatment-area after treatment/area before treatment) x100%;

It can be seen from Table 1 and Figure 2 that, after treatment with the walnut extract of the

present invention, the residual wound area was significantly reduced on the 7, 14, 21, and 28

days (p<0.05), compared with the NS group. After treatment with positive control rhEGF, the

residual wound area was significantly reduced on the 7, 14, 21, and 28 days (p<0.05).

TABLE 1 Residual wound area (%)

Residual wound area (%)( X +/- S) Group NO. Day7 Day 14 Day 21 Day 28

This 5 38.76% 11.24%' 6.04% ±2.22%' 2.60% ±1.74%' 0.59%±0.30%' invention rhEGF 5 34.66%± 9.04%2 12.19 ±10.56%2 6.13% ±6.01%2 1.05%±0.72%2

NS 5 63.57% ±13.14% 27.84%±12.19% 19.77% ±6.79% 11.33%±1.95%

1P<0.05, compared with NS; 2P<0.05, compared with NS

[0034] Table 2 shows that after the treatment of walnut extract in this application, the wound

healing rate increased significantly on the 7th, 14th, 21st and 28th days (p<0.05, compared to

the NS group). The positive control rhEGF increased the wound healing rate significantly on the

7th, 14th, 21st, 28th day after treatment (p<0.05, compared to the NS group). These data show

that the invention of this application has the effect of improving the healing rate of burn

wounds.

Table 2. Wound healing rate

Wound healing rate (%) (X +/- S) Group NO. Day7 Day14 Day21 Day28

This 1 99.41%±0.30 invention 5 61.24% 11.24%' 93.96% ±2.22%' 97.40%±1.74% 1

%2 .12 98.95%±0.72 rhEGF 5 65.34% 9.04%%2 87.81%±10.56% 93.87%±601% %2

88.67%±1.95 NS 5 36.43% 13.14% 72.16% ±12.19% 80.23% ±6.79%

P < 0.05, compared with NS; 2P < 0.05, compared with NS

[0035] Table 3 shows the wound healing time. From Table 3, it can be seen that the time

required to complete more than 90% wound healing is 14.20 ±1.11 days, 20.40 2.93 days in

the rhEGF group, and 33.00 ±1.70 days in the NS group. These data show that, compared with

normal saline, the walnut extract and growth factors of the present invention shorten the

healing time of the wound, and the walnut extract of the present application can make the

wound heal faster than the growth factor group.

Table 3. Wound healing time (days)

Wound healing time Group NO. F P ( X +/- S)

This invention 5 14.20 ±1.111,3

rhEGF 5 20.40 2.932 14.781 0.001

NS 5 33.00 1.70

1P<0.05, compared with NS; 2P<0.05, compared with NS; 3P<0.05 compared with rhEGF.

[0036] Through the evaluation of the curative effect of wound repair, the inventor found that

the walnut extract of the present application can significantly accelerate the healing speed of

burn wounds that are difficult to heal.

[0037] Example 4 Detection of epidermal proliferation and differentiation after wound repair

Reagents: CK10 primary antibody: Abcam, Cambridge, United Kingdom, 1:100; P63 primary

antibody: Biocare Medical, Concord, CA, United States, 1:200; secondary antibody: goat

anti-mouse IgG secondary antibody, OriGene Technologies, Inc, Beijing, China; Masson staining

kit: Solarbio, Beijing Solarbio Science & Technology Co., Ltd.

[0038] The expression proteins of epidermal proliferation and differentiation after wound

repair were localized and analyzed by immunohistochemistry technology. The results of

immunohistochemistry and Masson staining are shown in Figure 3 after 4 weeks of medication

on the wound.

[0039] The expression of P63 and CK10 protein means cell proliferation and differentiation.

Among them, P63 is mainly expressed in keratinocytes proliferating in the upper basal layer,

and keratin 10 (CK10) is mainly expressed in differentiated keratinocytes. The expression of P63

and CK10 protein shows the proliferation and differentiation of keratinocytes in the process of

epithelialization and repair of wounds. The higher the expression of P63 and CK10 protein, the

faster the proliferation and differentiation of cells, which leads to excessively thick proliferation

and differentiation layers in the epidermis, easily forming scars.

[0040] In the late stage of wound repair, fibroblasts secrete more collagen fibers, and a large

number of collagen fibers proliferate and are densely arranged. Masson staining is used to

indicate the subcutaneous collagen fibers as green. It can be seen from Figure 3 that after the

walnut extract of the present application is used to treat the wound, the structure of each layer

of the epidermis is clear. The immunohistochemical staining shows that the proliferation layer

and the differentiation layer are obvious and the expression of P63 and CK10 protein is weaker

than that of the growth factor group. , More conducive to inhibiting scar hyperplasia.

[0041] Through Image-Pro Plus 6.0, the positive protein P63 and CK10 integrated optical density

statistics are shown in Table 4. It can be seen that the IOD value of P63 in the walnut group is

higher than the normal saline group,, but significantly lower than the growth factor group

(P<0.05), indicating that the expression of P63 protein in walnut group was weaker than that of

growth factor group; while the IOD value of CK10 in walnut group was significantly lower than

that of normal saline group and growth factor group, indicating that CK10 protein expression in

walnut group was weaker than that of growth factor group and normal saline group (P <0.05).

This result further indicates that after the walnut extract of the present application is applied,

the wound is healed and scar hyperplasia is inhibited.

Table 4. Immunohistochemistry integrated optical density (IOD)

IOD (P63) IOD (CK10) Group F P F P ( X+/-S) ( X+/-S)

This322554 14555.87 ±2008.55", 223555.403 invention 15445.54

2 377548.09± rhEGF 18127.92 2605.75 6.289 0.003 17045.692 23.642 <0.001 17045.69

254773.14± NS 8074.32 1251.72 17658.03

P<0.05, compared with NS; 2P<0.05, compared with NS; 3P<0.05 compared rhEGF.

[0042] Furthermore, in this application, the distance between the upper and lower borders of

immunohistochemical staining of CK10 and P63 is used to measure the thickness of the

proliferation layer and the differentiation layer of each group after 4 weeks of treatment on the wound. The results are shown in Table 5. It can be seen that the proliferation layer in the walnut extract and growth factor group is thicker than the saline group, and the difference is statistically significant (P<0.05). Moreover, after the walnut extract of the present application is used to treat the wound, the thickness of the proliferation layer and the differentiation layer in the walnut extract group are thinner than the growth factor group, and the difference is statistically significant (P<0.05). This result further shows that the use of the walnut extract of the present application to treat wounds is more beneficial than growth factors in inhibiting scar hyperplasia.

Table 5. Comparison of the thickness of the proliferation layer with that of the differentiation

layer

The thickness of The thickness of the proliferation the differentiation Group layer F P layer F P

(X +/- S)(p1m) (X +/- S) (pm)

This 27.97 ±10.831,3 136.39 ±53.083 invention

rhEGF 36.41 ±10.602 31.437 0.001 245.91 ±83.512 32.35 <0.001

NS 17.60 ±4.94 131.43 ±43.12

P<0.05, this invention versus NS; 2P<0.05, rEGF versus NS; 3P<0.05, This invention versus

rhEGF.

[0043] The above results show that in the pig model of hard-to-heal wounds, the walnut extract

of the present invention has a significant healing effect on wounds, especially burns that are

hard to heal. Compared with the positive control rhEGF, the healing time of the walnut extract

of the present application is significantly shorter than that of growth factors; further, the

epidermal proliferation layer and differentiation layer are thinner than that of growth factors,

which is more conducive to inhibiting scar hyperplasia. It can be seen that the walnut extract of

the present application has a better therapeutic effect than the commonly used rhEGF.

[0044] Example 5 Verification of wound healing in burn patients

In clinical practice, wounds do not heal after one month with conventional treatment (silver ion

excipients combined with growth factors, 5,000 IU/mL/10 cm2) are usually referred to as

hard-to-heal wounds. In this application, a total of 60 patients with hard-to-heal wounds were

collected. Among them, 20 patients were treated with the walnut extract of the present

application, 20 patients were treated with surgery, and 20 patients were treated with

conventional dressing changes. The results are shown in Table 6 after 14 days of treatment.

Among them, the complete epithelialization of the wound is regarded as healing, the wound

healing rate > 75% is regarded as effective, and the wound healing rate 25% is regarded as

ineffective, and the effective rate = (the number of cured cases + the number of markedly

effective cases)/total number of cases. It can be seen from Table 6 that the total effective rate

of the walnut extract in this application and the surgery group in treating hard-to-heal burn

wounds is significantly higher than that of the conventional dressing change group, and the

difference is statistically significant (P<0.05). Compared with the surgery group, the effective

rate of the walnut extract of the present application has also significantly improved (P<0.05).

Moreover, the inventor found that after improving the extraction process of walnut extract, the

effective rate of the obtained walnut extract was further improved compared with the previous

study (effective rate 79.6%, Qian Chen et al., BURNS, 2020).

Table 6. Wound healing (cases/percentage)

Completely Effectively Improved Nothealed 2

Group NO healed case healed X test P (% (%)cas(%) case (%) case (%) case (%)

This 13 20 12 7 1 95.00%' application

Surgery 20 13 2 5 75.00%2 24.65 0.001 Conventional 20 0 2 18 10.00% treatment

P < 0.05 This invention versus Conventional treatment group; 2P < 0.05 Surgery group versus

Conventional treatment group; 3P > 0.05 This invention versus Surgery group.

[0045] Furthermore, this application has applied walnut extract treatment on infected wounds,

repeated non-healing wounds, and residual wounds that cannot treated with surgery. Among the 10 patients, the wounds were completely healed in 6 cases, markedly effective in 3 cases, and ineffective in 1 case. The effective rate is up to 90%. It can be seen that the walnut extract of the present application also has a good therapeutic effect on infected wounds, repeated non-healing wounds and residual wounds that cannot be treated by surgery.

[0046] The research above shows that the present application has an excellent therapeutic

effect on hard-to-heal burn wounds; the wound healing time is shorter; and it is more

conducive to inhibiting scar hyperplasia. In particular, the walnut extract of the present

application has a good therapeutic effect on infected wounds that cannot be treated by surgery,

repeated non-healing wounds and residual wounds, and therefore can be used to prepare

medicines for treating burn wounds. Moreover, the walnut extract of the present application

has a lower cost than EGF and surgical treatment, which is beneficial to clinical application and

popularization, and reduces the economic burden of patients.

[0047] The descriptions above are only the preferred embodiments of the present invention

and are not intended to limit the present invention. Any modification, equivalent replacement,

improvement, etc. made within the spirit and principle of the present invention shall be

included in the protection scope of the present invention.

Claims

1. The use of walnut extract in the preparation of a medicine for treating burn wounds, wherein the walnut extract contains the following ingredients:

Linolenic acid 250-300mg/g, Stearic acid 8-12 mg/g, Oleyl palmitamide 13-17 mg/g, Octadecanamide 8-12 mg/g, Tannic acid 10-15 mg/g, tyrosol 28-32mg/g, Oleamide 68-72mg/g and Activated charcoal 100-150 mg/g.

2. The use according to claim 1, wherein the burn wound is a non-healing burn wound.

3. A pharmaceutical composition comprising a walnut extract and a pharmaceutically acceptable carrier and/or excipient, wherein the walnut extract contains the following ingredients:

4. The pharmaceutical composition according to claim 3, wherein the dosage form of the pharmaceutical composition is an ointment.

5. The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable carrier and/or excipient is at least one selected from the group consisting of solvents, diluents, dispersants, suspending agents, surfactants, and isotonic agents, thickeners, emulsifiers, preservatives, adhesives, lubricants, hydrating agents, emulsification accelerators, absorbents, colorants, fragrances, release agents, coating agents, flavoring agents and antioxidants.

6. The use of the pharmaceutical composition according to any one of claims 3-5 in the preparation of a medicine for treating burn wounds.

7. The use according to claim 6, wherein the burn wound is a non-healing burn wound.